PMID- 38241548
OWN - NLM
STAT- MEDLINE
DCOM- 20240122
LR  - 20240202
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 103
IP  - 3
DP  - 2024 Jan 19
TI  - Effect of traditional Chinese medicine in osteosarcoma: Cross-interference of 
      signaling pathways and potential therapeutic targets.
PG  - e36467
LID - 10.1097/MD.0000000000036467 [doi]
LID - e36467
AB  - Osteosarcoma (OS) has a high recurrence rate, disability rate, mortality and 
      metastasis, it brings great economic burden and psychological pressure to 
      patients, and then seriously affects the quality of life of patients. At present, 
      the treatment methods of OS mainly include radiotherapy, chemotherapy, surgical 
      therapy and neoadjuvant chemotherapy combined with limb salvage surgery. These 
      treatment methods can relieve the clinical symptoms of patients to a certain 
      extent, and also effectively reduce the disability rate, mortality and recurrence 
      rate of OS patients. However, because metastasis of tumor cells leads to new 
      complications, and OS cells become resistant with prolonged drug intervention, 
      which reduces the sensitivity of OS cells to drugs, these treatments still have 
      some limitations. More and more studies have shown that traditional Chinese 
      medicine (TCM) has the characteristics of "multiple targets and multiple 
      pathways," and can play an important role in the development of OS through 
      several key signaling pathways, including PI3K/AKT, Wnt/beta-catenin, tyrosine 
      kinase/transcription factor 3 (JAK/STAT3), Notch, transforming growth factor-beta 
      (TGF-beta)/Smad, nuclear transcription factor-kappaB (NF-kappaB), mitogen-activated protein 
      kinase (MAPK), nuclear factor E2-related factor 2 (Nrf2), Hippo/YAP, 
      OPG/RANK/RANKL, Hedgehog and so on. In this paper, the signaling pathways of 
      cross-interference between active ingredients of TCM and OS were reviewed, and 
      the development status of novel OS treatment was analyzed. The active ingredients 
      in TCM can provide therapeutic benefits to patients by targeting the activity of 
      signaling pathways. In addition, potential strategies for targeted therapy of OS 
      by using ferroptosis were discussed. We hope to provide a unique insight for the 
      in-depth research and clinical application of TCM in the fields of OS growth, 
      metastasis and chemotherapy resistance by understanding the signaling crosstalk 
      between active ingredients in TCM and OS.
CI  - Copyright (c) 2024 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Liu, Yuezhen
AU  - Liu Y
AD  - Clinical College of Traditional Chinese Medicine, Gansu University of Traditional 
      Chinese Medicine, Lanzhou, China.
FAU - Jiang, Bing
AU  - Jiang B
AD  - Department of Integrated Chinese and Western Medicine, Gansu University of 
      Traditional Chinese Medicine, Lanzhou, China.
FAU - Li, Yanqiang
AU  - Li Y
AD  - Clinical College of Traditional Chinese Medicine, Gansu University of Traditional 
      Chinese Medicine, Lanzhou, China.
FAU - Zhang, Xiaoshou
AU  - Zhang X
AD  - Clinical College of Traditional Chinese Medicine, Gansu University of Traditional 
      Chinese Medicine, Lanzhou, China.
FAU - Wang, Lijun
AU  - Wang L
AD  - Clinical College of Traditional Chinese Medicine, Gansu University of Traditional 
      Chinese Medicine, Lanzhou, China.
FAU - Yao, Yasai
AU  - Yao Y
AD  - Clinical College of Traditional Chinese Medicine, Gansu University of Traditional 
      Chinese Medicine, Lanzhou, China.
FAU - Zhu, Baohong
AU  - Zhu B
AD  - Clinical College of Traditional Chinese Medicine, Gansu University of Traditional 
      Chinese Medicine, Lanzhou, China.
FAU - Shi, Hengwei
AU  - Shi H
AD  - The Second Affiliated Hospital of Gansu University of Traditional Chinese 
      Medicine, Lanzhou, China.
FAU - Chai, Xiping
AU  - Chai X
AD  - Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou, China.
FAU - Hu, Xingrong
AU  - Hu X
AD  - Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou, China.
FAU - Zhang, Bangneng
AU  - Zhang B
AD  - Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou, China.
FAU - Li, Hongzhuan
AU  - Li H
AUID- ORCID: 0009-0005-5711-2171
AD  - Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - 0 (NF-kappa B)
SB  - IM
MH  - Humans
MH  - *Medicine, Chinese Traditional
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Quality of Life
MH  - Signal Transduction
MH  - NF-kappa B/metabolism
MH  - *Osteosarcoma/drug therapy/metabolism
PMC - PMC10798715
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2024/01/19 18:30
MHDA- 2024/01/22 06:41
PMCR- 2024/01/19
CRDT- 2024/01/19 15:53
PHST- 2024/01/22 06:41 [medline]
PHST- 2024/01/19 18:30 [pubmed]
PHST- 2024/01/19 15:53 [entrez]
PHST- 2024/01/19 00:00 [pmc-release]
AID - 00005792-202401190-00023 [pii]
AID - 10.1097/MD.0000000000036467 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2024 Jan 19;103(3):e36467. doi: 
      10.1097/MD.0000000000036467.